Compare

Intuitive Surgical vs ResMed

MonkScore ranges and fundamentals, side by side

Key facts

Intuitive Surgical and ResMed: key facts

  • In fiscal 2025, Intuitive Surgical, Inc. reported revenue of $10.1B and net income of $2.9B.
  • In fiscal 2026, ResMed Inc. reported revenue of $5.7B and net income of $1.5B.
  • Intuitive Surgical, Inc.'s revenue grew 15.2% a year from fiscal 2021 to fiscal 2025.
  • ResMed Inc.'s revenue grew 12.1% a year from fiscal 2022 to fiscal 2026.
  • Intuitive Surgical, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • ResMed Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2022 to 2026.
  • In the twelve months to 30 September 2026, Intuitive Surgical, Inc. reported revenue of $11.6B and net income of $3.0B.
  • In the twelve months to 30 September 2026, ResMed Inc. reported revenue of $5.7B and net income of $1.6B.

Side by side

Intuitive Surgical and ResMed, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureIntuitive Surgical, Inc.NASDAQ:ISRGResMed Inc.NYSE:RMD
MonkScore
MonkScore range90–100as of October 202690–100as of October 2026
Sector rank23 of 628 in Healthcare73 of 628 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryMedical - Instruments & SuppliesMedical - Devices
Latest fiscal year
Revenue$10.1BFY 2025$5.7BFY 2026
Net income$2.9BFY 2025$1.5BFY 2026
Free cash flow$2.5BFY 2025$1.6BFY 2026
Operating cash flow$3.0BFY 2025$1.8BFY 2026
Total debt$302.8MFY 2025$825.9MFY 2026
Cash$3.4BFY 2025$1.5BFY 2026
Last 12 months
Revenue$11.6Bto 30 September 2026$5.7Bto 30 September 2026
Net income$3.0Bto 30 September 2026$1.6Bto 30 September 2026
Free cash flow$3.6Bto 30 September 2026$2.8Bto 30 September 2026
Operating cash flow$4.1Bto 30 September 2026$3.1Bto 30 September 2026
Total debt$0.0to 30 September 2026$610.6Mto 30 September 2026
Cash$3.0Bto 30 September 2026$1.0Bto 30 September 2026

MonkStreet provides research, not investment advice.